Atossa Genetics

1

January 9, 2013 A New Paradigm for Preventing Breast CancerThe Breast Health CompanyNASDAQ: ATOS

1Forward Looking StatementThis presentation has been prepared by Atossa Genetics, Inc. (the Company) as of January 8, 2013. It should not be considered as an offer or invitation to subscribe for or purchase any securities in the Company or as an inducement to make an offer or invitation with respect to those securities. It has been prepared for information purposes only. This presentation contains general summary information and does not take into account the investment objectives, financial situation and particular needs of any individual investor. It is not investment advice and prospective investors should obtain their own independent advice from qualified financial advisors having regard to their objectives, financial situation and needs.

Certain statements contained herein, including, without limitation, statements containing the words believes, intends and other words of similar import, constitute forward-looking statements within the meaning of section 7a of the Securities Act of 1933, as amended, and section 21e of the Securities Exchange Act of 1934, as amended. Such statements involve risks and uncertainties that could cause actual results to differ materially from projected results. Accordingly, investors should not place undue reliance on forward-looking statements as a prediction of actual results. The forward-looking statements may include projections and estimates, the timing and success of specific projects and our future operating results and financial condition. When we use the words "will," "believe," "intend," "expect," "may," "should," "anticipate," "could," "estimate," "plan," "predict," "project," or their negatives, or other similar expressions, the statements which include those words are usually forward-looking statements. When we describe strategy that involves risks or uncertainties, we are making forward-looking statements. The forward-looking statements in this presentation, if any, speak only as of the date of this presentation; we disclaim any obligation to update these statements. We have based these forward-looking statements on our current expectations and assumptions about future events. While our management considers these expectations and assumptions to be reasonable, they are inherently subject to significant business, economic, competitive, regulatory and other risks, contingencies and uncertainties, most of which are difficult to predict and many of which are beyond our control. Neither the delivery of this presentation nor any further discussions by the Company or its representatives with any of the recipients shall, under any circumstances, create any implication that there has been no change in the affairs of the Company since such date. This document contains confidential and proprietary information. Unauthorized possession, use or disclosure of the enclosed information is strictly prohibited and will be prosecuted under all applicable state and federal laws.

2Mission Statement

We are committed to building value for investors by preventing breast cancer with our patented, FDA-cleared products and our CLIA-based servicesMISSION STATEMENT

NASDAQ: ATOS3Mission Statement

GOAL FOR 2013

National launch of the ForeCYTE Breast Health Test, The Pap Smear for Breast Cancer$500 test for 110 Million women age 18-73 Tactical metrics5,000 Independent Sales Reps calling on33,000 Ob-Gyn MDs nationwide to generate$15,000 per MD per year in revenueAbout a 1% Market PenetrationNASDAQ: ATOS4

ForeCYTE Breast Health TestFDA-cleared non-invasive biopsy deviceMade in the USA CLIA-based test17 patents

5

How does ForeCYTE work?

AcellularCategory 0Category ICategory IICategory IIICategory IVMicroscopic ResultsFamily History ofBreast cancerPersonal Reproductive HistoryIBIS Risk Algorithm

(Peer reviewed algorithm developed from a registry of 158,041 women in whom 3,257 breast cancers occurred)Normal Risk20%6Care Path Business Model

ForeCYTE Value PropositionPotential to make mammograms (39 MM/year) virtually obsolete;Potentially eliminate the need for most of the nation's 1.2 million biopsies (at a cost of about $3500 each) and which require a needle to be jammed into the breast.MOST IMPORTANTLY, because the Atossa test spots abnormalities years before they can turn into tumors the test opens the door to eventual prevention of breast cancerJUST AS THE PAP SMEAR HAS VIRTUALLY ELMINATED CERVICAL CANCER (80% reduction) IN WOMEN WHO GET REGULAR SCREENING.

7Atossa Revenue ModelBreast Pump and Kit Sales to DoctorsSampling Kit Sales to DoctorsLaboratory Analysis with Report Generation

$500/patientLaboratory Service Revenue8Atossa Revenue ModelSampling Kit Sales to DoctorsLaboratory Analysis with Report Generation

Reimbursement

Faster payments for Atossa

1st Payer contract57 MM Americans coveredA stepping stone to In-network contracts over the next 2 years

9

Early ForeCYTE Adoption Demonstrates Significant Upside Potential34 MDs = $15,000 revenue/MD/yearCumulative Revenue x1000GrossProfit87%10

National ForeCYTE LaunchDistributor network focusedHenry Schein, McKesson, PSS World Medical, Cardinal Health, VWR, Vaxserve, Mercedes Medical, Fisher, NDC members, Imco members, B&H Surgical, Marshall Medical and Cascade HealthCare Products Collectively, over 5,000 employee or independent sales reps selling ForeCYTE products

11

Atossa Laboratory Tests

12Family History: No CancerFamily history: CancerLow Risk CytopathologyExpected resultsBiopsy-based ReassuranceHigh Risk CytopathologyBiopsy-based ConcernExpected ResultsCare Path Business Model

The Atossa Breast Health Care PathUS women age 18 to 73at risk of breast cancerNormal Risk0 to 15%Intermediate Risk15 to 20%High Risk>20%Newly DiagnosedBreast CancerBreast Cancer Survivors

1 sales rep

13Family History: No CancerFamily history: CancerLow Risk CytopathologyExpected resultsBiopsy-based ReassuranceHigh Risk CytopathologyBiopsy-based ConcernExpected ResultsCare Path Business Model

The Atossa Breast Health Care PathUS women age 18 to 73at risk of breast cancerStratify110 MMNormal Risk0 to 15%Intermediate Risk15 to 20%High Risk>20%Assess10 MMNewly DiagnosedBreast CancerBreast Cancer SurvivorsProfileMonitor0.2 MM2.5 MM1 sales rep

14Care Path Business Model

Intellectual PropertyFDA Medical Device Market Authorizations11 510(k) cleared and 2 510-exempt CLIA-based Laboratory Developed Tests4 validated testsPatents179 issued and 50 pendingTrademarks1 registered and 7 pending15Management TeamFamily History: No CancerFamily history: CancerLow Risk CytopathologyExpected resultsBiopsy-based ReassuranceHigh Risk CytopathologyBiopsy-based ConcernExpected ResultsCare Path Business Model

Experienced Management TeamCEOSteven C Quay, MD, PhD, FCAPCFOKyle Guse, Esq., CPACSOShu-Chih Chen, PhDVP Marketing & SalesChristopher DestroOperationsMichael Malafronte16

Key Financial MetricsRevenue: $383K (9 mos. ended 9/30/12)Gross Profit: $324K (9 mos. ended 9/30/12) Gross profit margin: 87% (9 mos. ended 9/30/12) Total Op Expenses: $3.7M Monthly burn rate (1H 2012) ~ $370KShareholder Equity: $3.4M (9/30/12)Shares Outstanding: 12.1M common; no preferred; 7.2M warrants at $1.56 per share

17Investment Summary

Breast Health Revenue; >85% Gross Margin Patented, FDA cleared products and services179 Issued Patents and 11 FDA-cleared devicesExperienced management teamTwo Key 2013 milestones: National roll out of ForeCYTE test with 5,000 sales repsAdvancing pipeline of additional products and services, including novel treatment approach

Investment ConsiderationsNASDAQ: ATOS18

NASDAQ: ATOS19